[关键词]
[摘要]
近年来血管内皮生长因子(VEGF)及其受体(VEGFR)成为抗肿瘤药物研发的重要靶点。甲磺酸阿帕替尼是一种抗VEGFR-2的小分子靶向药,用于晚期胃癌治疗。临床研究发现阿帕替尼不仅对胃癌疗效显著,而且在非小细胞肺癌、结直肠癌、乳腺癌等多种癌症的治疗中也有显著疗效。其临床用药形式从单独用药逐步发展为与多种治疗模式的联合应用。根据阿帕替尼的临床用药形式,分别从单独用药、联合其他化疗药用药、联合放疗用药等方面阐释阿帕替尼抗肿瘤的有效性和安全性,为临床合理用药提供参考。
[Key word]
[Abstract]
In recent years, vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have become important targets in the research and development of antineoplastic drugs. Apatinib mesylate is a small molecule targeting drug against VEGFR-2, which is used in the treatment of advanced gastric cancer. Clinical studies have found that apatinib is not only effective in the treatment of gastric cancer, but also in the treatment of non-small cell lung cancer, colorectal cancer, breast cancer and other cancers. The clinical application of apatinib has gradually developed from single drug use to combined application with a variety of treatment modes. According to the clinical application form of apatinib, the efficacy and safety of apatinib in anti-tumor were interpreted from the aspects of apatinib alone, combination with other chemotherapy drugs and combination with radiotherapy etc., so as to provide reference for clinical rational use of drugs.
[中图分类号]
R979.1
[基金项目]